sofosbuvir and daclatasvir

DRUG5 trials

Conditions

Chronic Hepatitis C InfectionHBV CoinfectionHepatitis B ReactivationHepatitis CHepatitis C Virus Infection, Response to Therapy ofHepatitis C, ChronicHuman Immunodeficiency Virus

Early Phase 1

Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera

NCT03882307

Assiut UniversityHepatitis C, Chronic

Start: 2022-10-31End: 2022-12-31Target: 40Updated: 2022-07-26

Phase 2

DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)

CompletedNCT02555943

Humanity and Health Research CentreChronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation

Start: 2015-02-28End: 2021-08-31Updated: 2021-09-01

Phase 3

Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients

CompletedNCT02576314

Humanity and Health Research CentreChronic Hepatitis C Infection

Start: 2015-05-31End: 2018-03-15Updated: 2018-03-19

Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus

CompletedNCT03369327

Tehran University of Medical SciencesHepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus

Start: 2017-01-01End: 2018-12-01Updated: 2019-02-20

Phase 4

Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 Patients

CompletedNCT03200184

Tehran University of Medical SciencesHepatitis C

Start: 2016-09-01End: 2018-09-01Updated: 2019-02-15

Related Papers

Single-pill sofosbuvir and daclatasvir for treating hepatis C in patients co-infected with human immunodeficiency virus.

2021-05-17

SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial

Clinical Infectious Diseases2019-07-0926 citations